Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491496 | 0.93 | NOS2 (0.65) | NOS2SLC6A4CYP2D6SLC6A2S1PR1 | |
| Fumaric Acid SCHEMBL6504718 | 0.85 | NOS2 (0.61) | NOS2SLC6A4CYP2D6SLC6A2S1PR1 | |
| Fumaric Acid SCHEMBL6504713 | 0.85 | NOS2 (0.61) | NOS2SLC6A4CYP2D6SLC6A2S1PR1 | |
| SCHEMBL6489634 | 0.81 | NOS2 (0.50) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6501101 | 0.81 | NOS2 (0.63) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL5652047 | 0.80 | NOS2 (0.84) | NOS2SLC6A4CYP2D6SLC6A2MRGPRX4 | |
| SCHEMBL6491135 | 0.78 | NOS2 (0.42) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6502590 | 0.76 | NOS2 (0.61) | NOS2SLC6A4CYP2D6SLC6A2S1PR1 | |
| SCHEMBL6554330 | 0.76 | NOS2 (0.61) | NOS2SLC6A4CYP2D6SLC6A2S1PR1 | |
| SCHEMBL6490913 | 0.76 | NOS2 (0.48) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223794-B2 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | claimed |
| US-20050143379-A1 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | US | claimed |
| US-7223794-B2 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| US-20050143379-A1 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143379-A1 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | CYP1A1, NOS3, NOS1 | NOS2 5/4885SLC6A4 1486/4885CYP2D6 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.